Vancouver, British Columbia — January 9, 2026 — Leads & Copy — Burcon NutraScience Corporation has increased the size of its previously announced non-brokered private placement of convertible debentures to an aggregate principal amount of up to $6.9 million, according to a news release.
The Private Placement has been conditionally approved by the Toronto Stock Exchange subject to Burcon complying with the terms of such conditional approval, including receipt of disinterested shareholder approval. For additional details, please refer to the Company’s news release dated January 2, 2026.
“We are encouraged by the strong investor interest in a challenging market,” said Kip Underwood, Burcon’s chief executive officer. “With continued support from insiders and major shareholders, we are accelerating our production and sales timeline and reaffirm our revenue target of more than $10 million for calendar 2026.”
Insiders of the Company and Burcon’s manufacturing partner owners are committed to participating at a minimum of $5.0 million in principal amount.
Burcon is a global technology leader in high-performance plant-based proteins for the food and beverage industry. Its commercial ingredients offer taste, texture, and functionality, making them ideal for formulators seeking next-generation protein solutions. Burcon holds an extensive patent portfolio covering novel proteins derived from pea, canola, soy, hemp, sunflower, and other plant sources. The company is committed to sustainability and to creating protein solutions that are better for people and the planet.
Paul Lam
Director, Investor Relations and Communications
Burcon NutraScience Corporation
490 – 999 West Broadway, Vancouver, BC, V5Z 1K5
Tel (604) 733-0896, Toll-free (888) 408-7960
plam@burcon.ca
Media Contact:
Steve Campbell, APR
President
Campbell & Company Public Relations
Tel (604) 888-5267
TECH@CCOM-PR.COM
Source: Burcon NutraScience Corporation
